Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoBORAY 70 EBIT per Share is $1.37 as of Dec. 2025. GuruFocus rates BORAY with a GF Score™ of 70/100 and a GF Value™ of $4.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 812 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 60.96% on this metric.
Bora Pharmaceuticals Co's EBIT per Share for the
three
months ended in Dec. 2025 was $0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.37.
During the past 12 months, the average EBIT per Share Growth Rate of Bora Pharmaceuticals Co was -11.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 14.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 59.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 76.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bora Pharmaceuticals Co's EBIT per Share or its related term are showing as below:
BORAY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -12.9 Med: 93 Max: 178.6
Current: 14.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bora Pharmaceuticals Co was 178.60% per year. The lowest was -12.90% per year. And the median was 93.00% per year.
BORAY's 3-Year EBIT Growth Rate is ranked better than 60.96% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs BORAY: 14.40
Bora Pharmaceuticals Co (OTCPK:BORAY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bora Pharmaceuticals Co EBIT per Share Related Terms
Bora Pharmaceuticals Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (BORAY) has a EBIT per Share of $1.37 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bora Pharmaceuticals Co and its competitors. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #317 out of 812 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Bora Pharmaceuticals Co's EBIT per Share too high?
Bora Pharmaceuticals Co's current EBIT per Share is $1.37. The Drug Manufacturers industry median EBIT per Share is 7.45. Bora Pharmaceuticals Co's value of $1.37 is 81.6% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #317 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EBIT per Share compare to ?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #317 out of 812 companies for EBIT per Share. This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median EBIT per Share is 7.45. Bora Pharmaceuticals Co's value of $1.37 is 81.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.45, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current EBIT per Share of $1.37 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EBIT per Share is $1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (BORAY) is currently considered Significantly Undervalued. The stock's GF Value™ is $4.84, compared to a current price of $2.59 — trading 46.5% below its estimated fair value. The current EBIT per Share is $1.37 and 81.6% below the Drug Manufacturers industry median of 7.45. Bora Pharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bora Pharmaceuticals Co (BORAY), the current EBIT per Share is $1.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (BORAY) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $2.59 is trading 46.5% below its estimated GF Value™ of $4.84.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for BORAY:
EBIT per Share: $1.37
GF Value™: $4.84 vs. price of $2.59 (46.5% below fair value)
Industry Position: 81.6% below the Drug Manufacturers median (#317 of 812)
No single metric tells the full story. See the BORAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
70GF Score
Get the complete analysis for BORAY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BORAY has been successfully added to your 
